Movement Alert|Regeneron Pharmaceuticals Intraday Rise 3.03% in Regular Trading, siRNA liver-fat data boosted sentiment

Market Focus11-10

On November 10, Regeneron Pharmaceuticals rose 3.03% in Regular Trading, with shares trading at $931.7551 and turnover reaching $295 million.

The move coincided with newly disclosed liver-targeted siRNA study results showing that a single subcutaneous dose reduced liver fat by 58% to 80% at week 36, with a dose-dependent effect, while the placebo group showed a 2.9% reduction.

Further details indicated that 93% of treated participants achieved at least a 30% reduction in liver fat, many patients returned to normal liver-fat levels, and ALT and AST markers also improved over time. The update followed recent strong third-quarter results, when revenue rose 36.3% year over year to $5.12 billion and non-GAAP diluted EPS reached $20.07, above consensus expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment